基因递送技术市场份额，规模，趋势，行业分析报告，按模式（生物[腺病毒，逆转录病毒，AAV，Lentivirus，其他病毒，非病毒），化学，物理）;通过申请（基因治疗，细胞疗法，疫苗，研究）;通过方法;按地区;分部预测，2021-2028
- Published Date: Apr 2021
- 页数：127
- Format: PDF
- 报告ID：PM1857
- Base Year: 2020
- 历史数据：2016-2019
Report Summary
The global gene delivery technologies market was valued at USD 2.64 billion in 2020 and is expected to grow at a CAGR of 15.0% during the forecast period. Gene therapies not only transformed genetic and hereditary disorders but have also played an important role in shaping the entire pharma landscape.
Know more about this report:请求样本页面
到2020年，市场上介绍了超过27种基因疗法，大约990家公司参与了研发和创新疗法的商业化。此外，高级疗法的不断变化的市场环境是促进基因交付技术市场的突出因素之一。
大多数基因递送技术在不同的研究环境中找到了市场应用，在临床环境中实施了很少。这主要是由于与每种模态类型相关的技术挑战，努力开发更高效的技术，而物理技术需要突破临床环境中的使用。
基因传递技术市场报告范围
The market is primarily segmented on the basis of mode, application, method, and geographic region.
By Mode |
By Application |
通过方法 |
By Region |
|
|
|
|
Know more about this report:请求样本页面
Insight by Mode
The biological vectors market segment accounted for the largest revenue share of gene delivery technologies industry in 2020 owing to a high success rate of Kymriah and Yescarta. These vectors have received greater attention, after the approval of vectors-based therapy products. An exponential rise in viral vector programs for research and development had shown its acceptance as one of the important delivery modes.
However, the chemical delivery method market segment is projected to witness a lucrative growth rate over the study period. Though in few settings, viral systems have faced clinical challenges which spurred the use of chemical methods. Chemical delivery systems are regarded as an alternative to viral delivery systems, due to their ability in combating challenges.
Physical delivery methods market segment have lower transfection efficiency in comparison with biological or chemical modes. Low cell viability is another major drawback in electroporation-based physical methods. However, such drawbacks create opportunities for other market players striving to gain more share, by addressing a high focus on transfection and cell viability issues.
方法洞察力
In 2020, the ex-vivo market segment of gene delivery technologies market accounted for the largest share. This high share is attributed to its transduction efficiency prior to cell implantation back to the patient’s body to have a less immunogenic response. Also, it has more transduction efficiency, makes it an ideal candidate to be used in research settings.
但是，基因交付技术市场的体内送货方式市场部门预计会在评估期内目睹利可多数的增长率。这是由于其对高度靶向基因交付的高偏好，如果出现错误，这会导致免疫应答。
此外，全世界科学家都专注于加速市场部门的研发。符合这一点，在2020年，俄勒冈州健康和科学大学部署了基因编辑工具“CRISPR-CAS9”，以编辑负责任何个人失明的遗传密码。这项高性能的行业事件预计将导致细分市场更好的财富。
Geographic Overview
In 2020, the North America region accounted for a significant share of the global market. Region’s gene delivery technologies demand growth is complemented by an increase in a substantial number of clinical trials in the pipeline to assess the efficacy of gene therapies to treat hereditary, cancer, genetic mutations, and rare disorders in the U.S.
Moreover, the presence of better clinical infrastructure with a majority of the companies engaged in the commerce of gene delivery products and accessories also boosted the gene delivery technologies industry growth prospects. The U.S has also started many collaborative research projects as a part of its Horizon 2020 plans. It will cover projects based on vector-based gene delivery trials for rare diseases.
相反，亚太基因交付技术行业预计在评估期内见证了利润丰厚的市场增长率。除了较大的人口大小和低劳动力成本外，该地区还发达了制药业。中国被视为枢纽基因治疗in terms of clinical trials of more than 1,000 were underway in past two years. Moreover, strong policy support in the concerned countries is also supporting the market growth in the region.
Competitive Insight
在基因交付技术市场中运营的着名球员是Horizo n Discovery Group Co.，Qiagen，牛津生物美景科，Signagen Laboratories，Hoffmann-La Roche Ag，Vectalys，Sirion-Biotech GmbH，Takara Bio Inc.，Bio-Rad Laboratories，Inc。，Thermo Fisher Scientific，Inc。，Origene Technologies，Inc。，System Biosciences，Promega Corporation和Catalent Inc.
